Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

The role of glutamate in anxiety and related disorders.

Cortese BM, Phan KL.

CNS Spectr. 2005 Oct;10(10):820-30. Review.

PMID:
16400245
2.

[Biological basis of anxiety disorders and serotonergic anxiolytics].

Inoue T, Izumi T, Li XB, Huang JZ, Kitaichi Y, Nakagawa S, Koyama T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Jun;24(3):125-31. Review. Japanese.

PMID:
15291241
3.

Glutamate and anxiety.

Bergink V, van Megen HJ, Westenberg HG.

Eur Neuropsychopharmacol. 2004 May;14(3):175-83. Review.

PMID:
15056476
4.

Overview of diagnosis and drug treatments of anxiety disorders.

Nutt DJ.

CNS Spectr. 2005 Jan;10(1):49-56. Review.

PMID:
15618947
5.

The neurobiology and control of anxious states.

Millan MJ.

Prog Neurobiol. 2003 Jun;70(2):83-244. Review.

PMID:
12927745
6.

Neurobiologic basis of anxiety and its treatment.

Salzman C, Miyawaki EK, le Bars P, Kerrihard TN.

Harv Rev Psychiatry. 1993 Nov-Dec;1(4):197-206. Review.

PMID:
9384849
7.
8.

Panic disorder: the potential role of serotonin reuptake inhibitors.

Sheehan DV, Zak JP, Miller JA Jr, Fanous BS.

J Clin Psychiatry. 1988 Aug;49 Suppl:30-6. Review.

PMID:
3045109
9.

Drug mechanisms in anxiety.

Bourin M, Hasco√ęt M.

Curr Opin Investig Drugs. 2001 Feb;2(2):259-65. Review.

PMID:
11816841
10.

[Recent trends in pharmacotherapy for anxiety disorders].

Tajima O.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Jun;24(3):133-6. Review. Japanese.

PMID:
15291242
11.

[Glutamatergic neurotransmission as molecular target in anxiety].

Carobrez Ade P.

Rev Bras Psiquiatr. 2003 Dec;25 Suppl 2:52-8. Epub 2004 Feb 16. Review. Portuguese.

12.

Animal models of anxiety: are they suitable for predicting drug action in humans?

Bourin M.

Pol J Pharmacol. 1997 Mar-Jun;49(2-3):79-84. Review.

PMID:
9437753
13.

Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders.

Keck PE Jr, Strawn JR, McElroy SL.

J Clin Psychiatry. 2006;67 Suppl 1:8-15. Review.

15.

Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

Palucha A.

Expert Opin Investig Drugs. 2006 Dec;15(12):1545-53. Review.

PMID:
17107280
16.

Future directions in anxiolytic pharmacotherapy.

Kunovac JL, Stahl SM.

Psychiatr Clin North Am. 1995 Dec;18(4):895-909. Review.

PMID:
8748388
17.

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.

Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD.

Nat Rev Drug Discov. 2005 Feb;4(2):131-44. Review.

PMID:
15665858
18.

Monoamine receptor systems and anxiety disorders.

Heninger GR, Charney DS.

Psychiatr Clin North Am. 1988 Jun;11(2):309-26. Review.

PMID:
2843838
19.

Serotonin and anxiety: current models.

Stein DJ, Stahl S.

Int Clin Psychopharmacol. 2000 Aug;15 Suppl 2:S1-6. Review.

PMID:
11110013
20.

Beyond monoamines: glutamatergic function in mood disorders.

Kugaya A, Sanacora G.

CNS Spectr. 2005 Oct;10(10):808-19. Review.

PMID:
16400244

Supplemental Content

Support Center